Clinical Trials & Surveys

Currently Recruiting Clinical Trials for Adrenal Diseases

“Those of us with adrenal disease know the importance of having new treatments that will give us an opportunity to have the best quality of life with improved medical options. Participation in clinical trials can help accelerate the development of new treatments and address our community’s unmet medical needs.”
— Lori Engler, NADF Co-President

For further information on these and other trials, go to clinicaltrials.gov.

All clinical trials listed below are for informational purposes only. NADF does not endorse these or any products.

MyAI Registry Re-Opens!

MyAI Patient-centered adrenal insufficiency research. NADF National Adrenal Diseases Foundation

Enrolling Participants for Online, Patient-Centered, Adrenal Insufficiency Study

If you have adrenal insufficiency – we want you!

We are looking to continue recruiting people for a large cohort study of adrenal insufficiency – with a focus on symptoms, diagnosis, quality of life, and outcomes of treatment.

Click here for more information

New Study: “Biomarker-Based Strategies for Optimizing Adrenal Insufficiency Management”

  • Sponsor: Mayo Clinic

  • Contact: Vanessa Fell fell.vanessa@mayo.edu

  • Enrolling adults diagnosed with classic CAH. The study uses an Oura Ring to better understand how sleep, activity, heart rate, temperature, glucocorticoid therapy, and medical events relate to day-to-day health in patients experiencing adrenal insufficiency.

RESET-MACS Study: A New Treatment Approach for Mild Autonomous Cortisol Secretion (MACS)

  • Sponsor: Mayo Clinic

  • Contact: Vanessa Fell fell.vanessa@mayo.edu

  • Adults age 18 years and older with diagnosed with Mild Autonomous Cortisol Secretion (MACS) may be eligible for a Mayo Clinic research study evaluating an investigational study drug, Metyrapone. The study lasts about 7 months, with an optional 6-month extension, and includes inpatient visits at Mayo Clinic in Rochester, Minnesota. Participants will be compensated for their time.

Learn more

Pharmacokinetic (PK), Pharmacodynamic (PD), and Tolerability of Osilodrostat in Pediatric Patients with Cushing’s Syndrome

Is your child suffering from Cushing’s syndrome? You may consider their participation in LINC-5 study which evaluates the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.

  • Sponsor: Recordati Rare Diseases

  • Who should consider participating: Children and adolescents 2 to <18 years of age with Cushing’s syndrome may qualify to participate in the LINC-5 study

  • To learn more, please reach out to your nearest research site:

Evaluating the Functional Status of the Adrenal Glands Hyperaldosteronism

Objective of this study is to see if a new radioactive tracer ([68Ga]Ga-PentixaFor) can make it easier to identify functional adrenal tumors leading to hyperaldosteronism.

  • Sponsor: National Cancer Institute

  • Principal Investigator:

  • Who should consider participation: People aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormone aldosterone.

Learn more

Updated Diagnostic Cortisol Values for Adrenal Insufficiency

The purpose of this study is to determine the cortisol levels that most accurately diagnose a patient with adrenal insufficiency, a condition in which cortisol levels are too low for daily living. 

  • ​Sponsor: Montefiore Medical Center

  • Contact: Smita B. Abraham, MD; email: smabraham@montefiore.org

  • Who should consider participating: If you are a male or a female, 18 years or older, consider participation to help determine the appropriate level of cortisol in healthy individuals to allow a more accurate diagnosis of people with adrenal insufficiency.

Learn more